studied changes in CD24, EpCAM, and FRα protein expression in ovarian cancer-derived exosomes to test whether a 3D-nanopatterned microfluidics device could perform non-invasive screening of cancer biomarkers. This evidence concerns the gene CD24 and ovarian carcinoma.